ZINBRYTA (daclizumab) withdrawn

As reported in various media outlets over the weekend, pharmaceutical companies Biogen and AbbVie have announced the voluntary worldwide withdrawal for ZINBRYTA ® (daclizumab) for Relapsing multiple sclerosis.

As stated in the official media release, patients currently treated with ZINBRYTA have been asked to contact their healthcare provider with any queries or concerns.

Biogen have specifically advised MS Australia that patients with enquiries about their treatments should speak with their treating Neurologist.

We will update you as more news comes to hand.

Biogen Press Release: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

Source: MS Australia



Call Us - 1800 042 138

MS Connect is our free telephone and email information support and referral service.

Register with MS

By registering with MS you can access our full range of services and support.


Donate Online


At MS we want everyone living with multiple sclerosis to get the support they need to live the best life they can. We want them to be more than their disease.

Your donations enable people living with multiple sclerosis to do all the everyday things we take for granted.

Join us in making MS stand for more than multiple sclerosis.
 

Donate Online

Stay informed with the latest from MS

Icon
TIS

Connect with us...